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Although amlodarone Is an effective d mg for re treatment of
IifeAhrentenlng ventrinemr arrhytsiov, rrte'townC oral oadtng
dose protocd has been defined, and ptknlo often undergo
prolonged brtgdtatiratlen fn- amindaeonr lw
:ng . High dose
(>i,66 mg/day) oral loading has usually bear rescrsed roe
uesmtge patients with lntessaat ventricular tl lyarrh!jhmiao .
The current study was designed to 1) exambr! the clin
;ral and
eleeteopt 1vlot gin
huts
of a high dose prat andndaroae Wading
region in mere stable ptewts
; and 2) ascertain Its safety and
t11
.+'r-, ; wbly idl"ir
.g shortened amiodarooe kwdece pert.
ads and potentially decreased length or hospital stay.
The study group Included
16 patients with a history of recur-
rent ventricular aebythmln red decreased left ventriniyr rune-
60a, who were refractory to prior
antiarkythmic drug therapy .
The oral lnadingp-otocot was 50 mg/kg per day ofamiodarone for
3 dews, then 30 niglkg per day for 2 days . followed by maintenance
therapy of 300 to 400 mg twice daily . Eleetrophysiologic testing
was performed
at baseline, on days I and 5 and during week 6 .
Amiodarone is an effective drug for the therapy of life
.
threatening ventricular arrhythmias 11), but treatment proto-
cols are not standardized in terms of loading dosage, length
of loading period or maintenance dosage. Loading doses of
400 Iv 1 .800 mg/day of amiodarune for I to 6 weeks, followed
by variable maintenance doses of 200 to 800 rg rd~sy . have
been reported to be effective in suppressing ventricular
arrhyrhmias and improving survival (2_6) . High loading
doses (>800 mg/day) have in general been avoided, predom-
inantly because of concern for precipitation of acute side
etecis, such as severe exacerbation of congestive heart
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Anliodarone and desethylamfodnrene levels were Measured and
symptoms monkcred .
Clinically . the high dose loading protocol was well tolerated in
13 of the 16 patimtr. Arrkylhmias were reordered nohiedsdble by
day 1 in three pulkuts and remained ---'- - "- throughout the
study period in two of the three
. The reinstating pad" motioned
to have inducible ventricular taehyedrdia. VentriCular 1sdlycAr-
din cyets length and right
ventricular
efedive refractory pvi-A
both progressively Inerprr(d ugciiiirne'y over brolhle, starting
a day 1 . The 15 patients who remained in the study had no
o eL'irard side effects during the loading period. Eleven pti uio
have bzen Mowed up for >2 yeas witdeot ay cliiral recur-
rence of their presenting arrhythmia
.
High dose oral amiodarone loading In ckudodly well tolerated
it patients with fffe•threulzdog ventrkalar artbythmlas who have
depressed ventricularfnectlw .This reghnet,gayc"_ A-oyy
1
loading periods, thereby permitting ,Sorter hospital gays in this
patient population,
(J Am Cull Cardiol 1992 ;79:169-73)
failure and proarrhythmia. However . two groups using oral
amiodaront. loading doses of up to 4
.4 g/day have reported
rapid suppression of spontaneous severe complex ventri v.u-
tar arrhythmia, (7,8). In addition, these dosages were clini-
cally well tolerated,
The selection ref the appropriate loading dose regimen still
poses a major challenge to clinicians because of amio-
darone's unusual pharmacokinetic protxrthts. It is a very
lipophilic drug with a half-life of up to 40 days, whose major
metabolite, desethylamiodarone, has an even longer half-life
than its parent compound (9) .
The antiarrhyttmic proletties
of amiodarone may be manifested before total body tissue
equilibration has occurred, and desethylumiddarone nay
cad,ibute to the overall long-term antiarrhythmic effects
(10)-
The uncertainties with regard to the short-term
adminis-
tration
of amiodarone are clinically signibcant
. High dose
oral amiodarone loading bee been previously studied in
patients with incessant ventricular arrhythmia, (8), a group
that comprises a relatively small proportion of the total
0715-I09T9253 .30
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population of patients with life-threate tins velanculat or-
rhythmias . The
present study was undertaken in patients
with a history of e-th•m ate. .^irb ventricular arrhythmias and
depressed ventricular function who do not have incessant
ventricular arehythuuas. The aims were I) to determine the
clinical tolerance of a high dose oral amiodorone loading
regimen in such patients : 21 to examine the electraphysio-
logic effects of such a high dose regimen both immediately
and at 6 weeks ; 3) to ascertain whether such n rcg4 tee, could
potentially be used to decrease the length of lime of amio-
darenc loading in this patient group ; and 4) to observe the
outcome Sunny !ong-term file
; s-tip .
Methods
Patients. Sixteen patients were initially entered into the
study . One patient, with a diagnosis of left vcnhicular
aneurysm secondary to myocardial infarction . congestive
heart failure and an ejection fraction of 12%, had an exacer-
bation of congestive heart failure after the first loading dose.
Although successfully treated with increased doses of diuret-
ics, he was withdrawn from the study at the request of his
physician and started on a regimen of lower doses of
amiodarone . No follow-up electrophysiologic testing was
performed in this patient . Thos, the study group included 15
patients (Table I) with a history of recurrent ventricular
tachycardia who had undergone a mean of 2 .7 prior unsuc-
cessful trials of antiarrtt imic drugs . The average age was
64 years, and the average ejection fraction was 29b . The
unde:lyiug eiiutngy wa. I,ahcmic heart disease in all pa-
tients . No patient had bad a myocardial infarction within the
month preceding the study . All patients Pad inducrhie sus-
tained
ventricular tachycardia, but no patient had incessant
ventricular arrhtlhmias.
Electrophysbltlgk testing protocol. After informed can-
sent was obtained, electrophysiologic testing was performed
with the patient in the postabsorptive state . All antiarrhyth-
mic therapy was discontinued for at least 5 half-lives before
the baseline electrophysiologic study was performed . The
details of our stimulation protocol have been reported pre-
viously
(I1). A new catheter was placed for each study, and
the same protocol followed. Ventricular tachycardia cycle
length, right ventricular effective refractory period at a
paring cycle length of 550 ms and two times diastolic
threshold, number ofexuastimuli required to induce ventric-
ular tachycardia, ventricular tachycardia configuration,
method of lachycmdia termination . and symptoms during
ventricular tachycardia were carefully recorded .
Amiodartne Wing. The dosing protocol was based au
prior high dose loading regimens J7,9) : 50 mf kg body weight
per day of oral amiodarone was given on days I through 3,
and 30 mglkg per day on days 4 and 5, after baseline
electrophysielogic testing . This protocol resulted in the
administration of 3 to 5 .2 Flday of amiodarone for the 1st 3
days, and of 1 .7 to 3 .1 g/day on days 4 and 5 . Maintenance
dosing was then instituted at 300 to 400 mg twice daily .
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kepeal eiechophysiologic studies were performed on days I
and 5 and at week 6 . Symptoms were closely monitored
during the loading phase, and plasma levels of amiudarone
and desethyiamiodarone wine measured at tae ti of the
repeal clectrophysiologic studies (whether or not this lime
represented the imerdosage trough point) .
Results
Elertrephysiobgk varhtbhs, Aii 15 patients who toler-
ated cn . fall h:¢ dose loading protocol underwent dedro-
phvsinhtgic
,
testing or baseline and on days I and 5 ; 13
patients had follow-up eleclmpbysiologic testing at week 611
moved away.
I refused further follow-upl
. The mean total
dose of amiedarone by day 5 was 11.9 g (Table I1. Clinical
and electrophysiol-)gic changes werrobseeved to start at day
I (Table 2) . At baseline, all 15 patients had inducible,
sustained ventricular tachycardia . By day l, ventricular
tachycardia was not inducible in two patients and only
nonsustained ventricular tachycardia was inducible in one
patient, At day 5, ventricular tachycardia remained nonin-
ducible in the two patients who had noninducible arrhythmia
on day I (one had ventricular fibrillation that was considered
to be a nanciinicat, rather than a proarrhylhmic response);
however, the patient with nonsustainest
ventricular
racby-
ear':a again had
stained
yrvtricular rnwi ycardia. At the 6
week follow-up, one o: the patients with previously index
ible arrhythmia crossed over into the group with noninduc-
ible arrhythmia (nonsustained ventricular tachyeardial, and
arrhythmia continued o be rmninducihle in the two patients
with previously noninducihle arrhythmia (with the same
patient having nanctinical ventricular fibriltat!o ..^p .
The ventricular tachycardia cycle length at baseline was
259 ± 64 ms (Table 2)
; by day 1, it had increased significantly
to 315 ± 101 ms (p < 0
.05 from day t)
. At day 5, there was
no significant increase over baseline or day I in )lu : ventric-
ular tachycardia cycle length, but by week ti the cycle length
had increased significantly to 37 .1
.
66 ms from day I and
day 5 (p < 0 .05 vs . baseline, day I and day 5). The right
ventricular effective refractory period followed a similar
pattern initially. The baseline right ventricular effective
refractory period was 252 ± 22 ms (Table 2), which in-
creased significantly to 279 ± 17 ms on day I (p < 0 .05) . On
day 5 there was no significant increase over baseline or day
I in the right ventricular effective refractory period, but by
week 6 it had significantly increased from day I to 307 `-
72 ms (p < (I .05 vs- besetine and day I)
. Them was no
consistent change in
number of extrastimuli necessary to
induce ventricular tachycardia associated with the increases
in ventriculu- tachycardia cycle length and right ventricular
effective refractory pertain . Seven patients had the same and
six patients had a different ventricular tachycardia config-
uration after receiving amiodaronc, but there was no signif-
icant difference in she increase in ventricular tachycardia
cycle length between the two groups. There was also no
consistent change in the symptoms reported during the
2ACC vd, 19, No
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Table 1. Clinical Chumoeristies and Cumulative Antiodarene lose on Day 5 in 15 Patients
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All values are mean velpes t SO. CABG = coronary artery bypn, ae, ;,.i-CHF= eoll1suve heart failure ;
EF = electron fm-ion: F = feelae : Hyposens = sympranaic hypaensivr. LVA = left veovieular anelrysln ;
M-male:MI=nyo;ardiolinfarcoon :SCD=suddeecardiacdea'h
:VF=-IocularEk;illaioe VT=rentrkdar
tachycardia.
ventricular tachycardia or in the method of tachycardia
termination .
I'hsr msiodamue and desethylandodaronp leveb. Plasma
amiodarone levels were 2.6
.
I mg/iter on day I liable 2) .
There was no ftmher significant change by day 5 or week 6 .
Desethy tvnindarone levels were 0.4 ± 0.2 mgititer on day I
(Table 21 However, by day 5 . the rev lr had risen signific-anuy
over day I values to 0.6 6 0.2 mglitcr (p < 0.05) and by week
6 had increased furfner l .1 l .1 { 03 mg/liter (p < 0 .09 vs . day
I and day 5).
SW effects . One pawith a left vacate star ejection
fraction of 12%, was withdrawn from the leading protocol
because of an exacerbation of congestive Sean failute . The
remaining 15 patients included in the study had no cardio-
vascular, neurologic or gastrointestinal symptoms during the
loading period. At 6 week follow-up, three patients had
developed new symptom. (tremor, insomnia and new con-
gestive heart tailure in one patient receiving 600 mg/day ;
171
slight incoordinalion and milu nausea in a patient receiving
800 mg/day and paresthesias and headache in a patient
receiving 800 mglday) . One pa dent was admitted to the
huspital I month after the week 6 fallow-up eleeimphysio-
ioglc study with a non Q wave myocardial infarction and
ventricular tachyerrdia of two different configurations from
that seen during the testing period ; he underwent successful
cardioversion .
fL:es~Glcis
High dose oral amiodarone loading was clinically well
tolerated in l5 of 16 patients with repressed ventricular
function and life-threatening ventricular arrhylhmias .
Elec-
trnphysiologic changes were mated by day 1, and continued
changes in the electraphysiologic variables were observed
through week 6 . Follow-up revealed good long-term sur-
vival .
Table 2. Eectrophysiolopic Findings and Amiadarone and Desethylamiodarone Levels in tllc i5 Study Patents
-, e, t =
p
< a.m versus baseline 1'1, day 1(1) or da15131
. p
V:.were o6ucivA 6y
I>
.i,.d Ilea usil she Bonferronconec0cs foe meaple rompansws .
Unless oo.-i. indicated, al values are mean vaues t SD. The numbers in Makers indicate the sapper of pa tent, (fray tin total whoa of 151 with the
measured variable . RVERP = right ventricular eFecdve refractory period; VF = , eanwlar hbrillcfan ; VT = ventricuhr each wudia ;
VICL = wiring.
laahycarna cycle kagih.
Variable Baseline
Day I Day 5 W.1,6
54 of patients with inducible VTNF 100% II51 405E 1151 93%(151 M (13I
VTCL (ms3 259 t 64 (151 315 ± 101 .
1121
340 t 134•
1131
373
1
56't ;1101
RVERP (ms), 252 : 22 (141 219 '- 17. [151 303 *_ 36.
1141
307 2 22-f 1131
Pouma aminda
.mre level (mylirer) 7 .6 7 11151 2 .0 s oh 114] 2.1 *- 0.41131
PI .-
desahllan:odsrone'svel (mppiren
0.4 - 021151 0.6 m 02-1131 1.1 a Itt It31
Symiaoms Indr C'mulaiw
Pr. Age (yrll Ilunng
Drug Ami b rave Dose
No Gender Duueovs VTNF Tnaa E ISr' on Day' 481
7EIM' CAF Hypolnns T I1-6
2 £SIM d1.CABG SCD 3 12 .6
I 61733
MI Chest pain 3 11 .6
4
57/f MLCABU Dimness 3 11 .3
7216
MI Syacape 12.0
$9/N Ml Syncope Hb
6 vM MLCABG Syncope 133
7//N MLLVA Syncope 11 .5
66M 1.11 SCD 3 13 .8
74/11 Mi,LVA SCD 7 11 .2
37114
. MLLVA Syncope 2 28 13 .5
12 611' M1 SCD 3 3" 108
13
67 M MI .CABG.LVA Syncope 3
16 9.9
14 7( V
MI
S'.__ 3
31 10
.7
15 6 /M
&I i
Dime. 35 10
Mean 6 2 .75 29% 1t .9
SD 03 10%
1
.4
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Clinical tolerance. Few studies air available document-
ing the short-term effects of high dose oral amiodarone
loading (7,g) . Apart from the our patient who was withdrawn
from the study because of symptomatic congestive hca•t
failure after the first lvatang dose, no patient experienced
symptoms of drug toxicity during the loading pc .iod . This
observation reveals that, even in patients with markedly
depressed left ventricular funduu, high dose loading is
unlikely to ause significant hemodytmmic compromise .
Hence, when urgent amiodarone loading is not required, this
regimen may be safer than rapid intravenous amiodarone
loading, which may result in hemodynamic compromise (12) .
Although not universally accepted, significant positive
correlations between plasma amiodarone levels and toxicity
stave seen previously reported (7, t3). T e paucity of symp-
toms in our patient group during the acute loading phase may
therefore relate to a nontoxic range of their scram amid
darone concentrations during the loading period . Not unex-
pectedly, several patients did experience minor symptoms
reported at the 6-week follow-up period, and the mainte .
nance dose of amiodarone was readjusted at that point .
Eledroph}sioiogk tfleets. The increases in ventricular
tachycardia cycle length and right ventricular effective re-
fractory period seen in our patients are similar to those
reported previously (2,3
.10,14-17) with lower dose loading
protocols and eleclrophysiologic testing performed I to
20 weeks after the it itiatior of amiodarone therapy . With the
loading protocol used in our study, significant prolongations
of the ventricular tachycardia cycle length and right ventric-
ular effective refractory period were already noted by day t .
Although still controversial, evidence suggests that dcc
trophysiologic testing may ne adsantarenus to predict ;ht
long-term outcome of amiodarone therapy (17-21)
. Report _d
positive prognostic indicators obtained during electrophy Bi-
ologic testing after amiodarone loading have included eo
.r,e plete suppression of arrhythmia inducibility (19,20). a
change from inducible sustained ventricular tachycardia to
nonsustained ventrcular tachycardia (17), improved hemo-
dynamic tolerance of th, induced arrhythmia (14) and an
increase in the cycle length of the induced ventriculra
tachycardia 121). Although early significant changes were
seen in the ventricular tachycardia cycle length and right
ventricular effective refractory period in our study. tachy-
cardia remained inducible in most patients . and there were
no significant changes in hamodynnmic tolerance of the
ventricular laehycardia .
The reasons for the disparity between the electrophysio
logic effects of amiodarone and its clinical efficacy are
unknown, but several groups, including ours, have reported
similar findings (2.3.14.15) . Hence, although nodinducibihty
of arrhythmia after amiodarone therapy may be a he:pfui
prognostic invicatur(19,22), treatment with a.miudarone may
confer significant protection from arrhythmia recurrence and
sudden cardiac death despite persistent inducibility (14,15)-
Amiodarone levels, The amiodarone levels achieved
within the I it 24 b Gfthe study were similar to those reported
IM'C v.a 19 . No. I
January 1992'.169-73
by Moslew el al, (8), whose patients received up to 4 4 g of
amiodarone daily- The e!eclrophysiologic effects of amio-
darone were also noted to he signifie''u :E a:; :tdn i ri s pert d . it
has been shown that there are measurable tissue amiodarone
levels after a single oral i7) or intmvc,toos (23) dose, a time
when deselhy lamiodarone levels area'- 'cent or low. Hence . it
is likely that amiodarone itself has etc trophysiologic effects
independent of those of desethylami darone
. and contrite.
utestotheoverall antiarrhythmicprnr ttiesofthedrug(24)
.
Although the amiodarone levels remained arable c'_r t„e
follow-up period, the desethylamindarone levels continued
in rise, in conjunction with a continued increase in the
ventricular tachycardia cycle length and night venrcular
effective refractory period . Similar results were reported by
Mitchell et al . (10). It has been postulated that desethylami-
odarone contributes to the antiarrhythmic effects of amio .
darone (10 24,25), Therefore, the further increases in the
electraphysiologic variables may have been in part related to
the higher desechytamiesarone levels, as well as to the
equilibration of amiodarone and desethylamiodarone
throughout all body tissues (23).
Several groups have examined the relation between ami-
odarone levels amt inducibility of ventricular tachycardia at
electrophysiologic study. No correlation has been observed
between plasma concentration of amiodarone or desethyla-
miodarone and inducibility of ventricular mchyeardia at
electrophysiologic study (3,22). number of estrastimuli re-
quired for induction (26) of
ventricular
tachycardia or clini-
cl recurrence of ventricular arrhythmia, .3,221- This sug-
g :sts That although the etectrapt:ysidloeic efiecif
,f
amiodarone are related to the plasma levels of amiodarone
and desethylarnfodarnne . monitoring of plasma levels in
addition to electlophysiolagic study is not helpful in predict-
ing the arrhythmia recurrence .
Laog•rerm follow-up. The patient initially excluded from
the study was no, followed up . In addition, two patients
were lost to follow-up lone moved away, one refused further
follow-ep)
. Two patients died of nonarrhythmic causes
3cithin 6 months of their 6-week follow-up electrophysiologic
study lone of intractable congestive heart failure and one of
metastatic carcinoma) . The remaining Il patients have all
been followed up for >2 years without clinical recurrence of
their presenting arrhythmia. One patient received an im-
plantable defibrillator. Amiodarone was discontinued in one
patient because of visual side effects thought to be secondary
to amioda: one, and mexilitene was substituted . Ten of the 15
patients continue to receive art» odarone . The clinical toler .
ance of amiodarone in the present study compares favorably
with results reported recently in two long-term follow-up
studies of much larger numbers of patients both at this
institutior. (271 and elsewhere (28)
.
Conclusions. The present study has shown that the use of
a high dose loading regimen of amiodarone is clinically well
tolerated in patients with life-threatening ventricular or-
rhythmnias and depressed ventricalr function . Furthermore,
the electrophysiologic effects of amiodarone are manifested
JACC Vet . 19. No, I
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early during high dose loading and may be due to the parent
drug. The further changes observed with time in electro-
phy:tialogic variables. despite stable amiodarone plasma
lelrels . suggest an additional effect of desethylamiodarane
Despite persistent arrhythmia indueib!!ity_ long-term fol-
low-up of these patients shows a survivsl rate similar to that
of patients who have received lower dose loading regimens .
Although there is a small potential to exacerbate preex-
isting depressed left ventricular function, the use of a high
dose oral amiodarone loading regimen appears to be clini-
cally safe . Because of its clinical safety snd good Ioleracce,
high dose oral amiodarone loading stay permit shorter
loading periods, thereby allowing a shorter nospital stay for
patients who reyts ;ro amiodarone therapy for life-threatening
ventricular arrhythmia. . Further studies with lzrger numbers
of patients are warranted to determine the best high dose
oral loading regimen .
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